Alaunos Therapeutics, Inc. Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount
Alaunos Therapeutics, Inc. (TCRT) reported Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount of $303.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-31.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets
us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount · last filed 2026-03-31
- Alaunos Therapeutics, Inc. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2025 was $303.00K, a 86.53% decline from fiscal 2024.
- Alaunos Therapeutics, Inc. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2024 was $2.25M.
- Alaunos Therapeutics, Inc. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2023 was -$25.80M, a 485.07% decline from fiscal 2022.
- Alaunos Therapeutics, Inc. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2022 was $6.70M, a 54.11% decline from fiscal 2021.
| Period end | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 12 month |
|---|---|
| 2025-12-31 | $303.00K 10-K · filed 2026-03-31 |
| 2024-12-31 | $2.25M 10-K · filed 2025-03-31 |
| 2023-12-31 | -$25.80M 10-K · filed 2024-04-01 |
| 2022-12-31 | $6.70M 10-K · filed 2023-03-07 |
| 2021-12-31 | $14.60M 10-K · filed 2022-03-30 |
| 2020-12-31 | $18.80M 10-K · filed 2021-03-01 |
| 2019-12-31 | $15.40M 10-K · filed 2020-03-02 |
| 2018-12-31 | -$2.90M 10-K · filed 2019-03-05 |
| 2017-12-31 | -$48.40M 10-K · filed 2018-03-01 |
| 2016-12-31 | $19.00M 10-K · filed 2017-02-16 |
| 2015-12-31 | $49.20M 10-K · filed 2016-02-24 |
| 2014-12-31 | $10.00M 10-K · filed 2015-02-26 |
| 2013-12-31 | $26.30M 10-K · filed 2014-03-03 |
| 2012-12-31 | $47.60M 10-K · filed 2013-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| Sunshine Biopharma Inc. (SBFM) | $0.003B | ||
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Aptevo Therapeutics Inc. (APVO) | United States | $0.003B | |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |